Patents by Inventor Catherine C. HEDRICK

Catherine C. HEDRICK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS
    Publication number: 20210340218
    Abstract: Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes; CD14+CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes; or CD14+CD16+ monocytes and/or CD14dimCD16+ (CD115+CD111b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 4, 2021
    Inventors: Catherine C. HEDRICK, Richard HANNA
  • Monocyte modulation and control of tumor metastasis
    Patent number: 11053297
    Abstract: Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+ GR1? (Ly6C?)) monocytes; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes; or CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 6, 2021
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Catherine C. Hedrick, Richard Hanna
  • MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS
    Publication number: 20180312568
    Abstract: Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+(CD115+CD11b+GR1?(Ly6C?)) monocytes; CD14+CD16+ monocytes and/or CD14dimCD16+(CD115+CD11b+GR1?(Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or sub-sequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+(CD115+CD11b+GR1? (Ly6C?)) monocytes; or CD14+CD16+ monocytes and/or CD14dimCD16+(CD115+CD11b+GR1?(Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.
    Type: Application
    Filed: October 27, 2016
    Publication date: November 1, 2018
    Applicant: La Jolla Institute for Allergy and Immunology
    Inventors: Catherine C. HEDRICK, Richard HANNA